Twist Bioscience TWST Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience Corporation stocks have been trading up by 9.74 percent after pivotal synthetic biology advances boosted investor optimism.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TWST

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Shares of TWST climbed between about 1.5% and more than 4% after announcing an antibody characterization data agreement tied to Eli Lilly’s AI-driven TuneLab drug discovery platform.
A new Lilly TuneLab deal integrates Twist Bioscience wet-lab antibody data directly into Lilly’s AI/ML models, reinforcing TWST’s role in AI-enabled biologics discovery.
Q3 FY26 revenue reached $118.4M, up over 23% year over year, with 14 straight growth quarters, gross margin at 52.8%, and full-year guidance raised to $456–457M.
UBS launched coverage of TWST with a Neutral rating but a high $144 price target versus a mean Street target of $87.56, while consensus remains at a Buy rating.
Pilot work with Anthropic on AI-designed mini-binder proteins is real and already folded into TWST’s fiscal 2027 outlook, limiting near-term surprise upside from that project.

Live Update At 16:47:00 EDT: On Thursday, September 17, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 9.74%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Twist Bioscience, ticker TWST, is starting to look less like a story stock and more like a business approaching a real profitability turn. In Q3 FY26, TWST printed $118.4M in revenue, up more than 23% year over year, marking its 14th straight quarter of growth. That kind of consistency matters for traders; it shows demand is not a one-quarter fluke.

Gross margin hit 52.8%, solid progress for a synthetic DNA and tools provider that used to bleed cash on every dollar of sales. Management raised full-year revenue guidance to a range of $456–457M and reiterated a target of adjusted EBITDA breakeven in Q4 FY26. For an early-stage tools name like Twist Bioscience, that “near breakeven” message can be a big sentiment driver.

There is still red ink. Recent filings show negative net income and weak return metrics, and key ratios flag a high price-to-sales multiple around 21.2 and heavy stock-based compensation. But the balance sheet for TWST shows ample liquidity, with a current ratio of 2.7 and modest leverage. That gives Twist Bioscience time to keep scaling.

More Breaking News

On the chart, TWST has been trending higher, closing at $155.56 on 2026/09/17 after a three-day run from the low $130s. Intraday action shows afternoon consolidation between roughly $157 and $160, suggesting active two-way trading rather than a blow-off spike.

Why Traders Are Watching TWST After The Lilly AI Deal

The real catalyst putting Twist Bioscience in front of momentum traders right now is the fresh agreement with Eli Lilly’s AI/ML drug discovery platform, TuneLab. TWST will provide antibody characterization data and related services, with Lilly researchers ordering antibody work through preferred Twist Bioscience protocols. In plain English, TWST becomes a data and wet-lab engine plugged straight into Lilly’s AI models for antibody discovery.

That is exactly the kind of “picks-and-shovels for AI in biotech” story traders on timothysykes.com and StocksToTrade hunt for. The market reaction backs that up. Multiple reports show TWST shares jumping, with gains ranging from roughly 1.5% to more than 4% on 2026/09/16 as news of the Lilly TuneLab deal hit. TWST wasn’t grinding up on rumors; it moved on a concrete partnership tied to a top-tier pharma name and a real AI workflow.

For TWST, the Lilly TuneLab integration is about more than headline value. Feeding high-quality antibody characterization data into Lilly’s models makes Twist Bioscience harder to rip out of that stack later. That hints at stickier, higher-margin revenue streams as AI-driven antibody design scales.

At the same time, management is trying to keep AI enthusiasm grounded. TWST confirmed that its pilot work producing and testing AI-designed mini-binder proteins for Anthropic is “probably sort of” already built into the company’s fiscal 2027 orders outlook. So yes, the Anthropic angle proves that Twist Bioscience’s platform can serve cutting-edge AI clients, but traders should not expect that project to suddenly blow up guidance.

UBS entering the scene adds another layer to the TWST trading narrative. The firm initiated coverage with a Neutral rating but set a striking $144 price target, well above the current analyst mean target of $87.56. That mix — cautious rating, aggressive target — tells traders that institutions see sizable upside if Twist Bioscience executes, even as they acknowledge risk at current valuations.

Ownership filings, including an amended Schedule 13G/A and a Form 4, show shifting stakes from a big holder and an insider or major shareholder. For active TWST traders, those moves are part of the normal churn that comes with a stock transitioning from story phase to execution phase.

Conclusion

Right now, Twist Bioscience sits at the crossroads of three hot themes: AI, biotech, and a path toward profitability. TWST is already acting like a go-to picks-and-shovels name for drug discovery, with synthetic DNA, next-gen sequencing tools, and now antibody characterization data feeding directly into Eli Lilly’s AI-driven TuneLab platform. That new deal helped push shares higher and reinforced the idea that TWST’s wet-lab engine is becoming embedded in major pharma workflows.

Under the hood, the numbers back up why traders are sticking with the story. Fourteen straight quarters of revenue growth, Q3 FY26 revenue of $118.4M, expanding gross margin at 52.8%, and raised full-year guidance to roughly $456–457M all show Twist Bioscience is not just selling a dream. Management’s aim for adjusted EBITDA breakeven in Q4 FY26 adds a clear milestone for TWST watchers to trade around.

There are still serious risks. TWST runs negative profit margins, trades at a rich price-to-sales ratio, and leans heavily on stock-based compensation. UBS’s Neutral rating, despite a lofty $144 target, is a reminder that execution has to keep matching the hype.

For now, though, the tape is confirming the story. TWST shares have been stair-stepping higher on strong volume and real news — not just chatter. As Tim Sykes likes to hammer home, “The trend is your friend, but only if you respect the risks and cut losses quickly.” As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.”. For traders tracking Twist Bioscience, that means treating the Lilly AI deal and the improving financials as catalysts, not guarantees, and staying disciplined as this high-beta name continues to move.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!